We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 20, 2022

Long-Term Immunosuppressives and In-Hospital COVID-19 Outcomes

The Lancet. Rheumatology


Additional Info

The Lancet. Rheumatology
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
Lancet Rheumatol 2022 Jan 01;4(1)e33-e41, KM Andersen, BA Bates, ES Rashidi, AL Olex, RB Mannon, RC Patel, J Singh, J Sun, PG Auwaerter, DK Ng, JB Segal, BT Garibaldi, HB Mehta, GC Alexander

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading